Gabon vs Sri Lanka: Average cost of multi drug-resistant tuberculosis treatment
Gabon
995 constant 2022 US$
in 2024
Sri Lanka
902 constant 2022 US$
in 2024
Gabon rank
50th
Sri Lanka rank
52nd
Average cost of multi drug-resistant tuberculosis treatment over time
- Gabon
- Sri Lanka
How they compare
Gabon currently reports 995 constant 2022 US$ against 902 constant 2022 US$ in Sri Lanka, a difference of 93 constant 2022 US$.
That makes Gabon's figure about 1.1 times Sri Lanka's.
The two have swapped places 3 times across 7 shared years of data; in 2018 it was Sri Lanka ahead.
Gabon ranks 50th and Sri Lanka ranks 52nd of 92 countries.
Sri Lanka has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Gabon | Sri Lanka | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 643.5 constant 2022 US$ | 3,386 constant 2022 US$ | 2,743 constant 2022 US$ | Sri Lanka |
| 2020s | 1,112 constant 2022 US$ | 1,439 constant 2022 US$ | 327 constant 2022 US$ | Sri Lanka |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Gabon or Sri Lanka?
- Gabon, at 995 constant 2022 US$ against 902 constant 2022 US$ in Sri Lanka as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Gabon and Sri Lanka?
- 93 constant 2022 US$, with Gabon ahead.
- How many years of comparable data are there for Gabon and Sri Lanka?
- 7 years are reported by both, from 2018 to 2024.
- How do Gabon and Sri Lanka rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Gabon ranks 50th and Sri Lanka ranks 52nd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.